10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   FOR THE QUARTERLY PERIOD ENDED  November 30, 2014

OR

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   FOR THE TRANSITION PERIOD FROM _______ TO ________.

COMMISSION FILE NUMBER: 0-52518

EVENT CARDIO GROUP INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada	20 - 8051714
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)
2798 Thamesgate Dr. Mississauga, Ontario, Canada	L4T 4E8
(Address of principal executive offices)	(Zip code)

Issuer's telephone number: 289-407-4377

 (Address of principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [x] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [x]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [x]

As of January 15, 2015, 88,497,702 shares of Common Stock, $0.001 par value, were outstanding excluding 1,412,619 shares owned by our subsidiary.

EVENT CARDIO GROUP INC.

CONTENTS TO FORM 10-Q

PART I --	FINANCIAL INFORMATION	Page
Item 1.	Financial Statements (Unaudited)	1
	Unaudited Consolidated Balance Sheets at November 30, 2014 and August 31, 2014	1
	Unaudited Consolidated Statements of Operations for the Three Months ended November 30, 2014	2
	Unaudited Statements of Changes in Stockholders’ Deficit for the Three Months ended November 30, 2014	3
	Unaudited Consolidated Statements of Cash Flows for the Three Months ended November 30, 2014	4
	Notes to Unaudited Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	14
Item 4.	Controls and Procedures	14
PART II -	OTHER INFORMATION	15
Item 1.	Legal Proceedings	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds from Sales of Registered Securities	15
Item 3.	Defaults Upon Senior Securities	15
Item 4.	Mine Safety Disclosures	15
Item 5.	Other Information	15
Item 6.	Exhibits	15
Signatures		16
Exhibit/Index

PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

EVENT CARDIO GROUP INC.

CONSOLIDATED BALANCE SHEETS

AS OF NOVEMBER 30, 2014 AND AUGUST 31, 2014

(Unaudited)

	November 30, 2014			August 31, 2014
ASSETS:
Current Assets
Cash	$	102,783		$	86,617
Total Current Assets		102,783			86,617
Property and Equipment, net		2,460			2,960
Financing Costs, net		29,390			40,097
Intangible Asset		499,064			—
TOTAL ASSETS	$	633,697		$	129,674
LIABILITIES AND STOCKHOLDERS' DEFICIT:
Current Liabilities
Accounts payable	$	123,115		$	56,197
Payables pursuant to license agreement		436,564			—
Due to shareholders		81,664			74,423
Total Current Liabilities		641,343			130,620
Long-Term Debt - Related Parties		580,183			384,978
TOTAL LIABILITIES		1,221,526			515,598
Stockholders' Deficit
Preferred stock, $0.001 par value; 10,000,000 shares authorized, 10,000,000 shares issued and outstanding		—			—
Common stock,190,000,000 shares authorized at $0.001 par value, 79,500,000 common shares issued and outstanding at August 31, 2014  and 87,082,773 at November 30, 2014		87,083			79,500
Additional paid in capital		99,300			—
Accumulated other comprehensive income (loss)		(11,157	)		4,999
Accumulated deficit		(763,055	)		(457,483	)
Total Event Cardio Group Inc. stockholders' deficiency		(587,829	)		(372,984	)
Non-controlling interest		—			(12,940	)
TOTAL STOCKHOLDERS' DEFICIENCY		(587,829	)		(385,924	)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	633,697		$	129,674

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents 1

EVENT CARDIO GROUP INC.

CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

FOR THE THREE MONTHS ENDED NOVEMBER 30, 2014 and 2013

(Unaudited)

	2014			2013
Revenue	$	—		$	—
Operating Expenses
General and administrative		106,659			5,561
Research and development		159,500			—
Total Operating Expenses		266,159			5,561
Loss from Operations		(266,159	)		(5,561	)
Other Expense
Interest expense - related parties		19,590			—
Net Loss		(285,749	)		(5,561	)
Other Comprehensive Income
Foreign currency translation adjustment		(16,156	)		—
Total Comprehensive Loss	$	(301,905	)	$	(5,561	)
Loss per Share - Basic and Diluted	$	(0.00	)	$	(0.00	)
Weighted Average Shares - Basic and Diluted		80,871,696			79,500,000

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents 2

EVENT CARDIO GROUP INC.

STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

FOR THE THREE MONTHS ENDED NOVEMBER 30, 2014

(Unaudited)

	Common Stock
	Common Shares		Amount		Additional Paid in Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Non-Controlling Interest			Total Stockholders' Deficiency
Balance, September 1, 2014		79,500,000	$	79,500	$	—	$	4,999		$	(457,483	)	$	(12,940	)	$	(385,924	)
Effect of reverse merger		6,882,773		6,883		—		—			(19,823	)		12,940			—
Issuance of shares		700,000		700		99,300		—			—			—			100,000
Net comprehensive loss		—		—		—		(16,156	)		(285,749	)		—			(301,905	)
Balance, November 30, 2014		87,082,773	$	87,083	$	99,300	$	(11,157	)	$	(763,055	)	$	—		$	(587,829	)

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents 3

 EVENT CARDIO GROUP INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED NOVEMBER 30, 2014 and 2013

(Unaudited)

	2014			2013
Cash Flows from Operating Activities
Net loss	$	(285,749	)	$	(5,561	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		500			—
Amortization of financing costs		10,707			—
Changes in assets and liabilities:
Accounts payable		66,918			5,189
Net cash used in operating activities		(207,624	)		(372	)
Cash Flows from Investing Activities
Purchase of intangible asset (see below)		(62,500	)		—
Net cash used in investing activities		(62,500	)		—
Cash Flows from Financing Activities
Advances from shareholders		7,241			332
Proceeds from long-term debt - related parties		195,205			—
Proceeds from issuance of shares		100,000			—
Net cash provided by financing activities		302,446			332
Effect of exchange rate on cash		(16,156	)		—
Increase (Decrease) in Cash		16,166			(40	)
Cash, beginning of period		86,617			11,481
Cash, end of period	$	102,783		$	11,441

The Company purchased an intangible asset for an aggregate of $499,064 for consideration of $62,500 cash, the assumption of a $62,500 note payable and the balance to be satisfied by the issuance of shares of common stock of the Company, valued at $375,064 at November 30, 2014, based on the stock price on that date.

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents 4

EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

November 30, 2014 and August 31, 2014

1. OVERVIEW

Description of Business

Sunrise Holdings Limited was incorporated on October 26, 2005 under the laws of Nevada. It changed its name to Event Cardio Group Inc. (the "Company") on November 7, 2014. The Company is developing a cardiac monitoring solution based on a wireless and leadless advance cardiac monitor. Upon completion of the development the device will collect medical data and transmit it to physicians for diagnostic evaluation. The Company also has a license agreement to distribute a patented product in the use of breast disease detection.

The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

Going Concern

As shown in the accompanying financial statements, the Company has not generated any revenue since inception, has incurred losses, and has an accumulated deficit of $763,055 as of November 30, 2014. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations, which it has not been able to accomplish to date, and/or obtain additional financing from its stockholders and/or other third parties.

These financial statements have been prepared on a going concern basis, which implies the Company will continue to meet its obligations and continue its operations for the next fiscal year. The continuation of the Company as a going concern is dependent upon financial support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, successfully locating and negotiating with other business entities for potential acquisition and/or acquiring new clients to generate revenues. There is no assurance that the Company will ever be profitable. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Basis of Presentation

The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of  November 30, 2014 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended November 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the form 8-K/A filed with the SEC on November 26, 2014. 

These financial statements contain the accounts of the Company and the accounts of the Company's subsidiaries 2340960 Ontario Inc. and EFIL Sub of ECG Inc. as at November 30, 2014 and August 31, 2014 Any inter-company accounts and transactions are eliminated.

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and are presented in United States Dollars.

Table of Contents 5

EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

November 30, 2014 and August 31, 2014

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

In preparing these financial statements in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting years. Actual results could differ from those estimates.

Fair Value Measurements

ASC 820, “Fair Value Measurements”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2, inputs other than level one that are either directly or indirectly observable such as quoted prices for identical or similar assets or liabilities on markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company had no assets or liabilities required to be recorded at fair value on a recurring basis as of November 30, 2014 or August 31, 2014.

Cash and Cash Equivalents

The Company considers all highly-liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of November 30, 2014 or August 31, 2014.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions.

Income Taxes

Under ASC 740, "Income Taxes", deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, the Company has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized.

Table of Contents 6

EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

November 30, 2014 and August 31, 2014

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

The Company files income tax returns in Canada and the United States with varying statutes of limitations. The Company's policy is to recognize interest expense and penalties related to income tax matters as a component of our provision for income taxes. There were no accrued interest and penalties associated with uncertain tax positions as of November 30, 2014.

Foreign Currency Translation

The Company's reporting and functional currency is the U.S. dollar. The Company's Canadian operation's functional currency is the Canadian dollar. The Company's U.S. subsidiary's functional currency is the U.S. dollar.

Transactions originating in Canadian dollars are translated to the functional currency of the US dollar as follows: using year end rates of exchange for financial assets and liabilities, average rates of exchange for the month of transaction for revenues and expenses and historical rates for property and equipment and equity.

The financial statements of the Company's Canadian operations are translated from the functional currency of the Canadian dollar into the reporting currency of the United States dollar in accordance with ASC 830, Foreign Currency Matters, using year end rates of exchange for assets and liabilities, average rates of exchange for the year for revenues and expenses and historical rates for equity.

Translation adjustments resulting from the process of translating the functional currency of Canadian dollar Canadian operation's financial statements into the reporting currency of U.S. dollar financial statements are included in determining comprehensive income. As of November 30, 2014 and August 31, 2014, the cumulative translation adjustment of $(11,157) and $4,999 respectively was classified as an item in accumulated other comprehensive income in the stockholders' deficit section of the balance sheet. For the period ended November 30, 2014 and November 30, 2013, the foreign currency translation adjustment to accumulated other comprehensive income was $(16,156) and $nil respectively.

Comprehensive Loss

Comprehensive loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, Accounting Standards Codification (ASC) 200, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. For the year presented, the Company's comprehensive loss includes net loss and foreign currency translation adjustments and is presented in the statement of operations.

Property and Equipment

Property and equipment consists of computer equipment, and is stated at cost. Property and equipment is depreciated using the straight-line method over the estimated service life of three years. Maintenance and repairs are expensed as incurred and improvements are capitalized. Gains or losses on the disposition of property equipment are recorded upon disposal.

Research and Development Expenses

All research and development costs are expensed as incurred.

Intangible Asset

License agreement is carried at cost, net of any impairment charges.

Table of Contents 7

EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

November 30, 2014 and August 31, 2014

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.

If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheet. For the years ended November 30, 2014 and August 31, 2014 there was an impairment charge of $nil and $nil, respectively with respect to license agreement.

3. PROPERTY & EQUIPMENT

Property and equipment consist of the following as of November 30, 2014 and August 31, 2014

	November 30, 2014		August 31, 2014
Computer	$	4,217	$	4,439
Accumulated depreciation		1,757		1,479
	$	2,460	$	2,960

4. INTANGIBLE ASSET

On October 24, 2014, the Company entered into a License Agreement with Life Medical Technologies, Inc. with respect to Life Medical’s “BreastCare DTS™” product and certain other technologies. The License Agreement grants the Company the exclusive right to distribute the BreastCare DTS™ in the United States, Canada and certain countries in Asia, including China. The Agreement calls for royalties of 5% on net sales, as defined in the License Agreement, and requires minimum annual royalties of $100,000 in 2015 and $200,000 each year thereafter.

The product is currently under development and as such the costs associated with the license agreement are not yet being amortized.

5. PAYABLES PURSUANT TO LICENSE AGREEMENT

As part of entering into the License Agreement described in note 4, the Company entered into release agreements with certain creditors of Life Medical Technologies, Inc. which held judgments against Life Medical in the aggregate amount of approximately $501,000. Pursuant to the Release Agreements, the Company agreed to pay those Creditors an aggregate of approximately $501,000, of which $125,000 is to be paid in cash ($62,500 of which remains unpaid at November 30, 2014) and the balance of which is to be satisfied by the issuance of shares of common stock of the Company, valued at $375,064 at November 30, 2014, based on the stock price on that date.

Table of Contents 8

EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

November 30, 2014 and August 31, 2014

6. DUE TO SHAREHOLDERS

The amounts due to shareholders are non-interest bearing, with no fixed terms of repayment, are payable on demand and are unsecured. As of November 30, 2014 and August 31, 2014, the amounts of due to shareholders are $81,664 and $74,423 respectively.

7. LONG-TERM DEBT - RELATED PARTIES

As at November 30, 2014, the Company has a promissory note outstanding to 2399371 Ontario Inc., a company owned by an affiliate, for $583,000 Canadian, bearing interest at 12% per annum, payable on December 1, 2015.

In connection with the entry into the License Agreement described in note 4, the Company borrowed CAD $79,106 ("the Loan") to be repaid on December 1, 2015, together with interest at the rate of 12% per annum from 9058583 Canada Inc. ("Lender") a corporation owned by the Company's majority shareholders. As additional consideration for the making of the Loan, the Company entered into a Sublicense agreement with the Lender whereby the Lender will be granted the exclusive rights to distribute the BreastCare DTS™ product in Canada with royalties payable at the rate of 5.5% of net sales, as to be defined in the Sublicense Agreement.

Included in general and administrative expenses for the three months ended November 30, 2014 is $19,590 and $nil for the three months ended November 30, 2013.

8. RELATED PARTY

The Company is related to Contex International Technologies (Canada) Inc. ("Contex") through the fact that the Company's shareholders also hold a 34% interest in 2419596 Ontario Inc, which owns Contex.

The Company has entered into a services agreement with Contex, whereby Contex will provide services related to the design and development of a wireless and leadless ECG cardiac monitor. The agreement runs for an initial term of one year to May 22, 2015 and will automatically renew for subsequent terms of one year unless notice of termination is given by either party in writing.

As at November 30, 2014 and November 30, 2013, $125,000 and $nil respectively, have been incurred related to this agreement and have been expensed in research and development expense.

See Note 7 regarding loan from related party.

9. BUSINESS COMBINATION

On September 8, 2014, the Company entered into a share exchange agreement with 2340960 Ontario Inc.'s shareholders whereby Sunrise acquired all of the issued and outstanding common shares of 2340960 Ontario Inc. in exchange for 79,500,000 common shares of the Company. Upon completion of this transaction, the shareholders of 2340960 Ontario Inc. now hold approximately 93.6% of voting control of the Company. This transaction, has been accounted for as a reverse merger with 2340960 Ontario Inc. being the acquirer and the Company being the acquiree. As part of this transaction, the Company has changed its fiscal year end from September 30th to August 31st.

10. SUBSEQUENT EVENTS

On January 6, 2015, the Company issued 2,827,548 shares of common stock as partial consideration for the payables pursuant to the licence agreement described in note 5. 

Table of Contents 9

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations. The words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “continue” and other similar expressions are intended to identify forward-looking statements. We have based these forward looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations and objectives, and financial needs. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Such risks and uncertainties include, among others, those discussed in our consolidated financial statements, related notes, and the other financial information appearing elsewhere in this report and our other filings with the Securities and Exchange Commission, or the SEC, particularly those contained in the Section entitled “Risk Factors” in our Form 10-K filed with the SEC on January 8, 2015. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. We do not intend, and undertake no obligation, to update any of our forward-looking statements after the date of this report to reflect actual results or future events or circumstances. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Our fiscal year ends on August 31 each year.

OVERVIEW

Event Cardio Group Inc. and its subsidiaries (collectively, “ECGI”, “we”, “our” or the “Company”) were organized on October 26, 2005 and have had no operations since December, 2008, when we discontinued our previous business of mineral exploration. Most of our activities since January, 2009 have been centered on the acquisition of a new business.

On June 9, 2014 we experienced a change of control as a result of a transaction (the “Transaction”) in which 1,412,619 shares of our common stock, par value $0.001 and 10,000,000 shares of our preferred stock, par value $0.001, constituting approximately 97% of the cumulative voting power of our capital stock on that date, was acquired by Mr. John Bentivoglio, who is now our sole director and chief executive officer, as nominee for 2340960 Ontario Inc., a private company organized in Ontario, Canada, which is doing business as Event Cardio Group and we hereinafter refer to as “ECG”. The shares acquired of record by Mr. John Bentivoglio on June 9, 2014 are now owned beneficially and of record by ECG. On September 8, 2014, we entered into a share exchange agreement (the “Exchange Agreement”), which we consummated on November 14, 2014, pursuant to which we acquired all of the issued and outstanding capital stock of ECG from ECG’s stockholders, The Nick Bozza Family Trust, The John Bentivoglio Family Trust and The Sgro (2010) Family Trust. In exchange for all of the outstanding capital stock of ECG, we issued to ECG’s stockholders an aggregate of 79,500,000 shares of our Common Stock (the “Share Exchange”). As a result of the consummation of the Share Exchange, (i) ECG became our wholly owned subsidiary and (ii) the ECG’s former stockholders own an aggregate of 79,500,000 shares which constituted approximately 92.8% of the cumulative voting power of our common stock on the date the share exchange was consummated.

Mr. John Bentivoglio, our sole director and chief executive officer is one of three trustees of The John Bentivoglio Family Trust, the beneficiaries of which are members of his family. In the future, we expect that Mr. Nick Bozza, one of the three trustees of The Nick Bozza Family Trust, the beneficiaries of which are members of his family, will be appointed to our Board of Directors (the “Board”) and serve as one of our executive officers.

Table of Contents 10

On October 24, 2014, through a wholly owned subsidiary, we entered into a license agreement (the “License Agreement”) with Life Medical Technologies, Inc. (“Life Medical”) under which we were granted the exclusive right to distribute Life Medical’s “BreastCare DTS™” in the United States and certain other territories. The BreastCare DTS™ product is a patented, non-invasive and FDA-cleared as an adjunct to mammography and other established procedures for the detection of breast disease, including breast cancer.

GENERAL

The Exchange Agreement is accounted for a reverse merger, in which ECG is deemed to be the acquiring entity for accounting purposes. The discussion and analysis of our financial condition and results of operations is based upon the financial statements of ECG which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of the Financial Statements requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities. On an on-going basis, the Company estimates on historical experience and on various other assumptions that, it believes to be reasonable under the circumstances, the results of which form the Company’s basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Reference is made to the Notes to the financial statements of 2340960 Ontario Inc. (which we refer to in this Report as ECG) for the periods ended August 31, 2014 and August 31, 2013, which is filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K/A filed with the SEC on November 26, 2014 (the “Financial Statements”), which should be read in conjunction with this Management Discussion below. The numbers and percentages contained in this Section are approximate.

The Company cannot predict what future laws and regulations might be passed that could have a material effect on its results of operations. The Company assesses the impact of significant changes in laws and regulations on a regular basis and updates the assumptions and estimates used to prepare its financial statements when it deems necessary.

The Company’s primary sources of funding to date have been capital contributions by its stockholders and cash provided by borrowings from affiliates. The Company’s primary uses of funds have been for capital expenditures, general and administrative expenses and research and development expenditures.

BASIS OF PRESENTATION

The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of November 30, 2014 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended November 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the form 8-K/A filed with the SEC on November 26, 2014.

These financial statements contain the accounts of the Company and the accounts of the Company’s subsidiaries 2340960 Ontario Inc. and EFIL Sub of ECG Inc. as at November 30, 2014 and August 31, 2014. Any inter-company accounts and transactions are eliminated.

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and are presented in United States Dollars.

Table of Contents 11

RESULTS OF OPERATIONS

We have been in the developmental stage since inception. Since inception, our efforts have been principally devoted to designing and developing a wireless cordless cardio monitor. From inception to November 30, 2014, the Company has sustained losses and has an accumulated deficit of $763,055.

Our loss from operations for the three months ended November 30, 2014 was $ 266,159 compared to a loss of $5,561 for the three months ended November 30, 2013. General and administrative expenses were $106,659 for the three-months ended November 30, 2014, compared to $5,561 for the three-months ended November 30, 2013, an increase of $101,098. This increase in general is predominately due to expenses related to the start-up of our business and expenses related to our expenses as a public company.

Also, we incurred research and development expenses of $159,500 during the period ended November 30, 2014 as compared to $0 during the comparable period in 2013, related to the development of our cardiac monitoring device.

Total comprehensive loss for the period ended November 30, 2014 was $301,905 as compared to $5,561 for the period ended November 30, 2013, an increase of $296,344, $260,598 of which resulted from the general and administrative and research development expenses described above.

LIQUIDITY AND CAPITAL RESOURCES

Period ended November 30, 2014 and August 31, 2014

As of November 30, 2014, our total assets were $633,697, total liabilities were $1,221,526 and stockholders’ deficit was $587,829 compared to $129,674, $515,598 and $385,924, respectively for the period ending August 31, 2014. Current assets at November 30, 2014 were $102,783 consisting of cash compared to $86,617 consisting of cash for the period ending August 31, 2014. Included in total assets as of November 30, 2014 are property, and equipment, net of depreciation of $2,460 net financing costs of $29,390, and an intangible asset of $499,064 compared to $2,960 of property net of depreciation and $40,097 of net financing costs, for the period ending August 31, 2014.

As of November 30, 2014, our total current liabilities were $641,343, consisting of stockholder loans in the amount $81,664 and accounts payable of $123,115 compared to current liabilities of $130,620, consisting of stockholder loans $74,423 and accounts payable of $56,197 for the period ending August 31, 2014. In addition, included in current asset on November 30, 2014 was $436,564 in payables we owed pursuant to our License Agreement with Life Medical, which license did not exist in the corresponding period in 2013. Our total liability for the period ended November 30, 2014 included long-term debts to related parties of $580,183 as compared to $384,978 long-term debts owed to related parties for the period ended November 30, 2014. The significant increase in our total liabilities in November 2014 compared to August 2014 resulted from the increase in our accounts payable, the long-term borrowing from related parties and payables owed pursuant to our License Agreement.

The net cash used in our operating activities in the three-month period ended November 30, 2014 was $(207,624), an increase of $207,252 from that used in the three-month period ended November 30, 2013 ($372), which net increase was affected by the increase in our net operating loss to $285,749 as compared to a net operating loss of $5,561 incurred in November 2013.

Net cash used in investment activities in the three-month period ended November 30, 2014 was ($62,500), as compared to ($0) in the comparable period in 2013, which increase was due to the acquisition of our License Agreement with Life Medical. Net cash from financing activities in the three-month period ended November 30, 2014 was $302,446, compared to $332 in the comparable period in 2013, which increase primarily related to proceeds from long-term related party financings.

Table of Contents 12

ECG has been in the developmental stage since inception. Since inception, ECG’s efforts have been principally devoted to designing and developing a wireless cordless cardio monitor. From inception to November 30, 2014, the Company has sustained losses and has an accumulated deficit of $763,055. The Company has funded its activities to date primarily through contributions from its stockholders and loans from affiliates.

In May 2014, ECG entered into a loan agreement (the “May Loan Agreement”) with an affiliated company, pursuant to which the lender agreed to lend the Company up to CAD $583,000. This loan bears interest at the rate of 12% per annum, compounded monthly, and matures on December 1, 2015. ECG’s shareholders guaranteed ECG’s obligations under the May Loan Agreement with recourse exclusively to the shares they owned of ECG. As a result of the Share Exchange, we have agreed to guaranty ECG’s obligations under the May Loan Agreement and pledge the shares of ECG that we acquired in the Shares Exchange to the lender as security for our guaranty. Our guaranty is secured by a lien on all of our assets. In addition, our Controlling Stockholders guaranteed ECG’s obligations under the May Loan Agreement with recourse exclusively to the shares of our common stock that they acquired in the Share Exchange. Under the terms of the May Loan Agreement, 50% of the net proceeds we realize from the sale of our capital stock or from borrowings must be used to repay the amounts owned under this Loan. As of November 30, 2014, CAD $583,000 (USD $510,183) is outstanding under the May Loan Agreement.

We are required to pay Life Medical royalties of 5% on net sales, as defined in the License Agreement, and minimum annual royalties of $100,000 in 2015 and $200,000 each year thereafter. In addition, we entered into release agreements (the “Releases”) with certain creditors (the “Life Medical Creditors”) of Life Medical which held judgments against Life Medical in the aggregate amount of approximately $501,000. Pursuant to the Release Agreements, we agreed to pay the Life Medical Creditors an aggregate of $501,000, of which $125,000 was to be paid in cash and the balance was to be satisfied by the issuance of shares of our common stock valued at $376,064.05, with the number of shares of common stock to be determined by dividing 376,064.05 by the volume weighted average price (“VWAP”) of our common stock as reported by Blumberg for the five (5) consecutive trading days ending on the day before the 15th calendar day after consummation of the Share Exchange. On January 6, 2015, we issued 2,827,548 shares of our common stock in satisfaction of this obligation. The recipients of shares valued at $70,000 are also to be paid in cash or shares of common stock, at our option, an amount equal to the excess, if any, of $70,000 over the value of such shares as of December 12, 2015. The License Agreement recognizes that in order to protect our interests, we may have to spend monies dealing with creditors of and other claimants against Life Medical. Although we have no obligation to consummate arrangements with such creditors, we may reduce any amounts we pay to Life Medical’s creditors from future amounts payable to Life Medical. We are currently conducting due diligence for the product, the strength of underlying patents, the status of required regulatory approvals and how this product can most efficiently be manufactured.

In connection with the License Agreement with Life Medical, in October 2014 we borrowed CAD $79,106 (the “October Loan”) from an Ontario corporation owned in equal thirds by John Bentivoglio, Nicholas Bozza and Frank Sgro (the “Lender”), all of whom are affiliates of the Company. This loan bears interest at the rate of 12% per annum, compounded monthly and matures on December 1, 2015. Our obligations under this Loan are secured by a lien on all of our assets as well as pledge of the stock we own in our wholly owned subsidiary which entered into the License Agreement.

As of November 30, 2014, we owed affiliates approximately $661,847.

We do not have substantial commitments for capital expenditures. However, we will require financing to complete the development of our cardiac monitor, to provide the working capital necessary to implement our business plan and to expand our business. If we fail to arrange for such financing in the future, we will not be able to complete the development of our cardiac monitor or execute our business plan until we can obtain adequate financing, which we may not be successful in accomplishing. We may not be able to obtain financing in sufficient amounts or on acceptable terms when needed, which will adversely affect our prospects. We will need to raise the financing necessary to meet our anticipated cash requirements for the foreseeable future.

Table of Contents 13

OFF BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements, financings, or other relationships with consolidated entities or other persons, also known as “special purpose entities”.

CRITICAL ACCOUNTING POLICIES

Our significant accounting policies are more fully described in Note 2 to the Financial Statements provided in Part I, Item 1 of this report. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures of contingent assets and liabilities. Actual results could differ from those estimates under different assumptions or conditions.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a smaller reporting company, this item is not applicable to us.

ITEM 4. CONTROLS AND PROCEDURES

a) Disclosure Controls and Procedures

We maintain "disclosure controls and procedures," as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

At the end of the period covered by this report we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, John Bentivoglio, of the effectiveness of the design and operation of our disclosure controls and procedures. This evaluation included an evaluation of our financial controls. Since our Chief Executive Officer also serves as our Chief Financial Officer and we do not have financial and accounting personnel thoroughly familiar with U.S. GAAP and U.S. securities laws and regulations, we have a deficiency in our financial controls. This deficiency in our financial controls and procedures constitutes a deficiency in our disclosure controls and procedures in that our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in our periodic reports is recorded, processed, summarized and reported, within the time periods specified for each report and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. This deficiency will not be considered remediated until we hire accounting personnel with the requisite knowledge and experience concerning U.S. GAAP and the U.S. securities laws.

b) Changes in Internal Control over Financial Reporting

There were no changes in the Company's internal control over financial reporting that occurred during the last fiscal quarter ended November 30, 2014, that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents 14

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may be involved in various legal proceedings in the ordinary course of business. We do not believe that any settlement or judgment regarding current or potential future legal proceedings will have a material effect on our financial position.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS FROM SALES OF REGISTERED SECURITIES

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibits
21	List of subsidiaries
31	Sec. 302 Certification of CEO/CFO
32	Sec. 906 Certification of CEO/CFO

Table of Contents 15

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Event Cardio Group Inc.
Dated: January 20, 2015	By:	/s/ John Bentivoglio
	Name: Title:	John Bentivoglio Chief Executive Officer acting Chief Financial Officer (Principal Executive Officer and Principal Accounting Officer) Director

Table of Contents 16

EX-21

Exhibit 21

List of subsidiaries

2340960 Ontario Inc.

EFIL Sub of ECG Inc.

EX-31

Exhibit 31

CERTIFICATION

I, John Bentivoglio, Chief Executive Officer Acting Chief Financial Officer (Principal Executive Officer and Principal Accounting Officer) of the registrant, certify that:

1. I have reviewed this annual report on Form 10-Q of Event Cardio Group Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15d-15(f) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal controls over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 20, 2015

John Bentivoglio

Chief Executive Officer

Acting Chief Financial Officer

(Principal Executive Officer and Principal Accounting Officer)

EX-32

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Interim Report of Event Cardio Group Inc. (the "Registrant") on Form 10-Q for the interim period ended November 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John Bentivoglio, Chief Executive Officer acting Chief Financial Officer (Principal Executive Officer and Principal Accounting Officer) of the Registrant, certify, in accordance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report, to which this certification is attached as Exhibit 32, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant

Date: January 20, 2015

John Bentivoglio

Chief Executive Officer

acting Chief Financial Officer

(Principal Executive Officer and Principal Accounting Officer)

XML

6. DUE TO SHAREHOLDERS (Details Narrative) (USD $)	Nov. 30, 2014	Aug. 31, 2014
Notes to Financial Statements
Due to Shareholders	$ 81,664	$ 74,423

XML

3. PROPERTY & EQUIPMENT

3 Months Ended

Nov. 30, 2014

Property, Plant and Equipment [Abstract]

3. PROPERTY & EQUIPMENT

3. PROPERTY & EQUIPMENT

Property and equipment consist of the following as of November 30, 2014 and August 31, 2014

	November 30, 2014		August 31, 2014
Computer	$	4,217	$	4,439
Accumulated depreciation		1,757		1,479
	$	2,460	$	2,960

XML

10. SUBSEQUENT EVENTS (Details Narrative) (Subsequent Event [Member])	3 Months Ended
	Nov. 30, 2014
Subsequent Event [Member]
Stock Issued in Partial Consideration for Payables	2,827,548

XML

9. BUSINESS COMBINATION (Details Narrative) (Equity Issued in Business Combination [Member])	3 Months Ended
	Nov. 30, 2014
Equity Issued in Business Combination [Member]
Shares Issued in Business Combination	79,500,000
Voting Control Percentage	93.60%

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Nov. 30, 2014

Accounting Policies [Abstract]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

In preparing these financial statements in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting years. Actual results could differ from those estimates.

Fair Value Measurements

ASC 820, “Fair Value Measurements”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2, inputs other than level one that are either directly or indirectly observable such as quoted prices for identical or similar assets or liabilities on markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company had no assets or liabilities required to be recorded at fair value on a recurring basis as of November 30, 2014 or August 31, 2014.

Cash and Cash Equivalents

The Company considers all highly-liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of November 30, 2014 or August 31, 2014.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions.

Income Taxes

Under ASC 740, "Income Taxes", deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, the Company has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized.

The Company files income tax returns in Canada and the United States with varying statutes of limitations. The Company's policy is to recognize interest expense and penalties related to income tax matters as a component of our provision for income taxes. There were no accrued interest and penalties associated with uncertain tax positions as of November 30, 2014.

Foreign Currency Translation

The Company's reporting and functional currency is the U.S. dollar. The Company's Canadian operation's functional currency is the Canadian dollar. The Company's U.S. subsidiary's functional currency is the U.S. dollar.

Transactions originating in Canadian dollars are translated to the functional currency of the US dollar as follows: using year end rates of exchange for financial assets and liabilities, average rates of exchange for the month of transaction for revenues and expenses and historical rates for property and equipment and equity.

The financial statements of the Company's Canadian operations are translated from the functional currency of the Canadian dollar into the reporting currency of the United States dollar in accordance with ASC 830, Foreign Currency Matters, using year end rates of exchange for assets and liabilities, average rates of exchange for the year for revenues and expenses and historical rates for equity.

Translation adjustments resulting from the process of translating the functional currency of Canadian dollar Canadian operation's financial statements into the reporting currency of U.S. dollar financial statements are included in determining comprehensive income. As of November 30, 2014 and August 31, 2014, the cumulative translation adjustment of $(11,157) and $4,999 respectively was classified as an item in accumulated other comprehensive income in the stockholders' deficit section of the balance sheet. For the period ended November 30, 2014 and November 30, 2013, the foreign currency translation adjustment to accumulated other comprehensive income was $(16,156) and $nil respectively.

Comprehensive Loss

Comprehensive loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, Accounting Standards Codification (ASC) 200, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. For the year presented, the Company's comprehensive loss includes net loss and foreign currency translation adjustments and is presented in the statement of operations.

Property and Equipment

Property and equipment consists of computer equipment, and is stated at cost. Property and equipment is depreciated using the straight-line method over the estimated service life of three years. Maintenance and repairs are expensed as incurred and improvements are capitalized. Gains or losses on the disposition of property equipment are recorded upon disposal.

Research and Development Expenses

All research and development costs are expensed as incurred.

Intangible Asset

License agreement is carried at cost, net of any impairment charges.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.

If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheet. For the years ended November 30, 2014 and August 31, 2014 there was an impairment charge of $nil and $nil, respectively with respect to license agreement.

XML

Balance Sheets (Unaudited) (USD $)	Nov. 30, 2014	Aug. 31, 2014
Current Assets
Cash	$ 102,783	$ 86,617
Total Current Assets	102,783	86,617
Property and Equipment, net	2,460	2,960
Financing Costs, net	29,390	40,097
Intangible Asset	499,064
TOTAL ASSETS	633,697	129,674
Current Liabilities
Accounts payable	123,115	56,197
Payables pursuant to license agreement	436,564
Due to shareholders	81,664	74,423
Total Current Liabilities	641,343	130,620
Long-Term Debt - Related Parties	580,183	384,978
TOTAL LIABILITIES	1,221,526	515,598
Stockholders' Deficit
Preferred stock, $0.001 par value; 10,000,000 shares authorized, 10,000,000 shares issued and outstanding
Common stock,190,000,000 shares authorized at $0.001 par value, 79,500,000 common shares issued and outstanding at August 31, 2014 and 87,082,773 at November 30, 2014	87,083	79,500
Additional paid in capital	99,300
Accumulated other comprehensive income (loss)	(11,157)	4,999
Accumulated deficit	(763,055)	(457,483)
Total Event Cardio Group Inc. stockholders' deficiency	(587,829)	(372,984)
Non-controlling interest		(12,940)
TOTAL STOCKHOLDERS' DEFICIENCY	(587,829)	(385,924)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 633,697	$ 129,674

XML

Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Nov. 30, 2014	Nov. 30, 2013
Cash Flows from Operating Activities
Net loss	$ (285,749)	$ (5,561)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	500
Amortization of financing costs	10,707
Changes in assets and liabilities:
Accounts payable	66,918	5,189
Net cash used in operating activities	(207,624)	(372)
Cash Flows from Investing Activities
Purchase of intangible asset (see below)	(62,500)
Net cash used in investing activities	(62,500)
Cash Flows from Financing Activities
Advances from shareholders	7,241	332
Proceeds from long-term debt - related parties	195,205
Proceeds from issuance of shares	100,000
Net cash provided by financing activities	302,446	332
Effect of exchange rate on cash	(16,156)
Increase (Decrease) in Cash	16,166	(40)
Cash, beginning of period	86,617	11,481
Cash, end of period	102,783	11,441
Intangible Asset Purchase	499,064
Cash paid for Intangible Asset	62,500
Assumption of Note Payable for Acquisition of Intangible Asset	62,500
Stock Issued in Acquisition of Intangible Asset	$ 375,064

XML

3. PROPERTY & EQUIPMENT - Property & Equipment (Details) (USD $)	Nov. 30, 2014	Aug. 31, 2014
Accumulated depreciation	$ 1,757	$ 1,479
Property Plant Equipment, Net	2,460	2,960
Computer
Property Plant Equipment	$ 4,217	$ 4,439

XML

5. PAYABLES PURSUANT TO LICENSE AGREEMENT (Details Narrative) (USD $)	3 Months Ended
	Nov. 30, 2014
Payables and Accruals [Abstract]
Judgements against Life Medical	$ 501,000
Cash due to Creditors	125,000
Balance Due to Creditors	(62,500)
Issuance of Common Stock to satisfy Creditors, Value	$ 375,064

XML

1. OVERVIEW

3 Months Ended

Nov. 30, 2014

Accounting Policies [Abstract]

1. OVERVIEW

1. OVERVIEW

Description of Business

Sunrise Holdings Limited was incorporated on October 26, 2005 under the laws of Nevada. It changed its name to Event Cardio Group Inc. (the "Company") on November 7, 2014. The Company is developing a cardiac monitoring solution based on a wireless and leadless advance cardiac monitor. Upon completion of the development the device will collect medical data and transmit it to physicians for diagnostic evaluation. The Company also has a license agreement to distribute a patented product in the use of breast disease detection.

The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

Going Concern

As shown in the accompanying financial statements, the Company has not generated any revenue since inception, has incurred losses, and has an accumulated deficit of $763,055 as of November 30, 2014. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations, which it has not been able to accomplish to date, and/or obtain additional financing from its stockholders and/or other third parties.

These financial statements have been prepared on a going concern basis, which implies the Company will continue to meet its obligations and continue its operations for the next fiscal year. The continuation of the Company as a going concern is dependent upon financial support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, successfully locating and negotiating with other business entities for potential acquisition and/or acquiring new clients to generate revenues. There is no assurance that the Company will ever be profitable. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Basis of Presentation

The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of  November 30, 2014 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended November 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the form 8-K/A filed with the SEC on November 26, 2014. 

These financial statements contain the accounts of the Company and the accounts of the Company's subsidiaries 2340960 Ontario Inc. and EFIL Sub of ECG Inc. as at November 30, 2014 and August 31, 2014 Any inter-company accounts and transactions are eliminated.

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and are presented in United States Dollars.

XML

Balance Sheets (Parenthetical) (USD $)	Nov. 30, 2014	Aug. 31, 2014
Statement of Financial Position [Abstract]
Preferred Stock Par Value	$ 0.001	$ 0.001
Preferred Stock Shares Authorized	10,000,000	10,000,000
Preferred Stock Shares Issued	10,000,000	10,000,000
Preferred Stock Shares Outstanding	10,000,000	10,000,000
Common Stock Par Value	$ 0.001	$ 0.001
Common Stock Shares Authorized	190,000,000	190,000,000
Common Stock Shares Issued	87,082,773	79,500,000
Common Stock Shares Outstanding	87,082,773	79,500,000

XML

1. OVERVIEW (Policies)

3 Months Ended

Nov. 30, 2014

Accounting Policies [Abstract]

Description of Business

Description of Business

Sunrise Holdings Limited was incorporated on October 26, 2005 under the laws of Nevada to engage in any lawful corporate undertaking. It changed its name to Event Cardio Group Inc. (the "Company") on November 7, 2014. The Company is developing a cardiac monitoring solution based on a wireless and leadless advance cardiac monitor. Upon completion of the development the device will collect medical data and transmit it to physicians for diagnostic evaluation. The Company also has a license agreement to distribute a patented product in the use of breast disease detection.

The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

Going Concern

Going Concern

As shown in the accompanying financial statements, the Company has not generated any revenue since inception, has incurred losses, and has an accumulated deficit of $763,055 as of November 30, 2014. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations, which it has not been able to accomplish to date, and/or obtain additional financing from its stockholders and/or other third parties.

These financial statements have been prepared on a going concern basis, which implies the Company will continue to meet its obligations and continue its operations for the next fiscal year. The continuation of the Company as a going concern is dependent upon financial support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, successfully locating and negotiating with other business entities for potential acquisition and/or acquiring new clients to generate revenues. There is no assurance that the Company will ever be profitable. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Basis of Presentation

Basis of Presentation

The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of  November 30, 2014 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended November 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the form 8-K/A filed with the SEC on November 26, 2014. 

These financial statements contain the accounts of the Company and the accounts of the Company's subsidiaries 2340960 Ontario Inc. and EFIL Sub of ECG Inc. as at November 30, 2014 and August 31, 2014 Any inter-company accounts and transactions are eliminated.

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and are presented in United States Dollars.

XML

Document and Entity Information	3 Months Ended
	Nov. 30, 2014	Jan. 15, 2015
Document And Entity Information
Entity Registrant Name	Event Cardio Group Inc.
Entity Central Index Key	0001394130
Document Type	10-Q
Document Period End Date	Nov. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		88,497,702
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Nov. 30, 2014

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

In preparing these financial statements in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting years. Actual results could differ from those estimates.

Fair Value Measurements

Fair Value Measurements

ASC 820, “Fair Value Measurements”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2, inputs other than level one that are either directly or indirectly observable such as quoted prices for identical or similar assets or liabilities on markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company had no assets or liabilities required to be recorded at fair value on a recurring basis as of November 30, 2014 or August 31, 2014.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly-liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of November 30, 2014 or August 31, 2014.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions.

Income Taxes

Income Taxes

Under ASC 740, "Income Taxes", deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, the Company has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized.

The Company files income tax returns in Canada and the United States with varying statutes of limitations. The Company's policy is to recognize interest expense and penalties related to income tax matters as a component of our provision for income taxes. There were no accrued interest and penalties associated with uncertain tax positions as of November 30, 2014.

Foreign Currency Translation

Foreign Currency Translation

The Company's reporting and functional currency is the U.S. dollar. The Company's Canadian operation's functional currency is the Canadian dollar. The Company's U.S. subsidiary's functional currency is the U.S. dollar.

Transactions originating in Canadian dollars are translated to the functional currency of the US dollar as follows: using year end rates of exchange for financial assets and liabilities, average rates of exchange for the month of transaction for revenues and expenses and historical rates for property and equipment and equity.

The financial statements of the Company's Canadian operations are translated from the functional currency of the Canadian dollar into the reporting currency of the United States dollar in accordance with ASC 830, Foreign Currency Matters, using year end rates of exchange for assets and liabilities, average rates of exchange for the year for revenues and expenses and historical rates for equity.

Translation adjustments resulting from the process of translating the functional currency of Canadian dollar Canadian operation's financial statements into the reporting currency of U.S. dollar financial statements are included in determining comprehensive income. As of November 30, 2014 and August 31, 2014, the cumulative translation adjustment of $(11,157) and $4,999 respectively was classified as an item in accumulated other comprehensive income in the stockholders' deficit section of the balance sheet. For the period ended November 30, 2014 and November 30, 2013, the foreign currency translation adjustment to accumulated other comprehensive income was $(16,156) and $nil respectively.

Comprehensive Loss

Comprehensive Loss

Comprehensive loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, Accounting Standards Codification (ASC) 200, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. For the year presented, the Company's comprehensive loss includes net loss and foreign currency translation adjustments and is presented in the statement of operations.

Property and Equipment

Property and Equipment

Property and equipment consists of computer equipment, and is stated at cost. Property and equipment is depreciated using the straight-line method over the estimated service life of three years. Maintenance and repairs are expensed as incurred and improvements are capitalized. Gains or losses on the disposition of property equipment are recorded upon disposal.

Research and Development Expenses

Research and Development Expenses

All research and development costs are expensed as incurred.

Intangible Asset

Intangible Asset

License agreement is carried at cost, net of any impairment charges.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.

If the carrying amount of an asset exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheet. For the years ended November 30, 2014 and August 31, 2014 there was an impairment charge of $nil and $nil, respectively with respect to license agreement.

XML

Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Nov. 30, 2014	Nov. 30, 2013
Income Statement [Abstract]
Revenue
Operating Expenses
General and administrative	106,659	5,561
Research and development	159,500
Total Operating Expenses	266,159	5,561
Loss from Operations	(266,159)	(5,561)
Other Expense
Interest expense - related parties	19,590
Net Loss	(285,749)	(5,561)
Other Comprehensive Income
Foreign currency translation adjustment	(16,156)
Total Comprehensive Loss	$ (301,905)	$ (5,561)
Loss per Share - Basic and Diluted	$ 0.00	$ 0.00
Weighted Average Shares - Basic and Diluted	80,871,696	79,500,000

XML

6. DUE TO SHAREHOLDERS

3 Months Ended

Nov. 30, 2014

Notes to Financial Statements

6. DUE TO SHAREHOLDERS

6. DUE TO SHAREHOLDERS

The amounts due to shareholders are non-interest bearing, with no fixed terms of repayment, are payable on demand and are unsecured. As of November 30, 2014 and August 31, 2014, the amounts of due to shareholders are $81,664 and $74,423 respectively.

XML

5. PAYABLES PURSUANT TO LICENSE AGREEMENT

3 Months Ended

Nov. 30, 2014

Payables and Accruals [Abstract]

5. PAYABLES PURSUANT TO LICENSE AGREEMENT

5. PAYABLES PURSUANT TO LICENSE AGREEMENT

As part of entering into the License Agreement described in note 4, the Company entered into release agreements with certain creditors of Life Medical Technologies, Inc. which held judgments against Life Medical in the aggregate amount of approximately $501,000. Pursuant to the Release Agreements, the Company agreed to pay those Creditors an aggregate of approximately $501,000, of which $125,000 is to be paid in cash ($62,500 of which remains unpaid at November 30, 2014) and the balance of which is to be satisfied by the issuance of shares of common stock of the Company, valued at $375,064 at November 30, 2014, based on the stock price on that date.

XML

4. INTANGIBLE ASSET (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Nov. 30, 2014	Aug. 31, 2016	Aug. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Royalties Percentage	5.00%
Minimum Annual Royalties		$ 200,000	$ 100,000

XML

3. PROPERTY & EQUIPMENT (Tables)

3 Months Ended

Nov. 30, 2014

Property, Plant and Equipment [Abstract]

Property & Equipment

	November 30, 2014		August 31, 2014
Computer	$	4,217	$	4,439
Accumulated depreciation		1,757		1,479
	$	2,460	$	2,960

XML

9. BUSINESS COMBINATION

3 Months Ended

Nov. 30, 2014

Business Combinations [Abstract]

9. BUSINESS COMBINATION

9. BUSINESS COMBINATION

On September 8, 2014, the Company entered into a share exchange agreement with 2340960 Ontario Inc.'s shareholders whereby Sunrise acquired all of the issued and outstanding common shares of 2340960 Ontario Inc. in exchange for 79,500,000 common shares of the Company. Upon completion of this transaction, the shareholders of 2340960 Ontario Inc. now hold approximately 93.6% of voting control of the Company. This transaction, has been accounted for as a reverse merger with 2340960 Ontario Inc. being the acquirer and the Company being the acquiree. As part of this transaction, the Company has changed its fiscal year end from September 30th to August 31st.

XML

7. LONG-TERM DEBT - RELATED PARTIES

3 Months Ended

Nov. 30, 2014

Debt Disclosure [Abstract]

7. LONG-TERM DEBT - RELATED PARTIES

7. LONG-TERM DEBT - RELATED PARTIES

As at November 30, 2014, the Company has a promissory note outstanding to 2399371 Ontario Inc., a company owned by an affiliate, for $583,000 Canadian, bearing interest at 12% per annum, payable on December 1, 2015.

In connection with the entry into the License Agreement described in note 4, the Company borrowed CAD $79,106 ("the Loan") to be repaid on December 1, 2015, together with interest at the rate of 12% per annum from 9058583 Canada Inc. ("Lender") a corporation owned by the Company's majority shareholders. As additional consideration for the making of the Loan, the Company entered into a Sublicense agreement with the Lender whereby the Lender will be granted the exclusive rights to distribute the BreastCare DTS™ product in Canada with royalties payable at the rate of 5.5% of net sales, as to be defined in the Sublicense Agreement.

Included in general and administrative expenses for the three months ended November 30, 2014 is $19,590 and $nil for the three months ended November 30, 2013.

XML

8. RELATED PARTY

3 Months Ended

Nov. 30, 2014

Related Party Transactions [Abstract]

8. RELATED PARTY

8. RELATED PARTY

The Company is related to Contex International Technologies (Canada) Inc. ("Contex") through the fact that the Company's shareholders also hold a 34% interest in 2419596 Ontario Inc, which owns Contex.

The Company has entered into a services agreement with Contex, whereby Contex will provide services related to the design and development of a wireless and leadless ECG cardiac monitor. The agreement runs for an initial term of one year to May 22, 2015 and will automatically renew for subsequent terms of one year unless notice of termination is given by either party in writing.

As at November 30, 2014 and November 30, 2013, $125,000 and $nil respectively, have been incurred related to this agreement and have been expensed in research and development expense.

See Note 7 regarding loan from related party.

XML

10. SUBSEQUENT EVENTS

3 Months Ended

Nov. 30, 2014

Subsequent Events [Abstract]

10. SUBSEQUENT EVENTS

10. SUBSEQUENT EVENTS

On January 6, 2015, the Company issued 2,827,548 shares of common stock as partial consideration for the payables pursuant to the licence agreement described in note 5. 

XML

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	3 Months Ended
	Nov. 30, 2014	Aug. 31, 2014
Accounting Policies [Abstract]
Cumulative Translation Adjustment	$ (11,157)	$ 4,999
Foreign Currency Translation Adjustment to Accumulated other Comprehensive Income	$ (16,156)

XML

7. LONG-TERM DEBT - RELATED PARTIES (Details Narrative) (USD $)	3 Months Ended
	Nov. 30, 2014	Nov. 30, 2013
General and Administrative Expense	$ 19,590	$ 0
Canada, Dollars | 2399371 Ontario Inc.
Promissory Note Balance	583,000
Note Interest Rate	12.00%
Canada, Dollars | 9058583 Canada Inc.
Promissory Note Balance	$ 79,106
Note Interest Rate	12.00%

XML

Shareholders Equity (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income / Loss	Accumulated Deficit	Noncontrolling Interest	Total
Beginning Balance, Value at Aug. 31, 2014	$ 79,500		$ 4,999	$ (457,483)	$ (12,940)	$ (385,924)
Beginning Balance, Shares at Aug. 31, 2014	79,500,000
Effect of reverse merger, Shares	6,882,773
Effect of reverse merger, Value	6,883			(19,823)	12,940
Issuance of shares, Shares	700,000
Issuance of shares, Value	700	99,300				100,000
Net comprehensive loss			(16,156)	(285,749)		(301,905)
Ending Balance, Value at Nov. 30, 2014	$ 87,083	$ 99,300	$ (11,157)	$ (763,055)		$ (587,829)
Ending Balance, Shares at Nov. 30, 2014	87,082,773

XML

4. INTANGIBLE ASSET

3 Months Ended

Nov. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

4. INTANGIBLE ASSET

4. INTANGIBLE ASSET

On October 24, 2014, the Company entered into a License Agreement with Life Medical Technologies, Inc. with respect to Life Medical’s “BreastCare DTS™” product and certain other technologies. The License Agreement grants the Company the exclusive right to distribute the BreastCare DTS™ in the United States, Canada and certain countries in Asia, including China. The Agreement calls for royalties of 5% on net sales, as defined in the License Agreement, and requires minimum annual royalties of $100,000 in 2015 and $200,000 each year thereafter.

The product is currently under development and as such the costs associated with the license agreement are not yet being amortized.

XML

8. RELATED PARTY (Details Narrative) (USD $)	3 Months Ended
	Nov. 30, 2014	Nov. 30, 2013
Research and Development Expense	$ 125,000
Ontario Inc 2419596 [Member]
Ownership Percentage	34.00%

XML

1. OVERVIEW (Details Narrative) (USD $)	Nov. 30, 2014	Aug. 31, 2014
Accounting Policies [Abstract]
Accumulated Deficit	$ (763,055)	$ (457,483)